Considering that TNF-α-TNFR1 signaling is crucial in the regulation of immune responses that occur under conditions of limited immunostimulatory capacity, such as tumor surveillance [49], we anticipate that targeting TNFR1 would bring synergic anti-tumor effects by inhibiting CTGF-mediated EMT in tumor cells and modifying TNF-mediated inflammatory responses. The gene discussed is TNF; the disease is neoplasm.